State Street Corporation reported beneficial ownership of 5,021,441 shares of Ultragenyx Pharmaceutical Inc. common stock, representing 5.1% of the class as of 03/31/2026. The filing lists shared voting power of 4,769,004 shares and shared dispositive power of 5,021,441 shares. The filing is a Schedule 13G disclosure signed on 05/12/2026 by Elizabeth Schaefer.
Positive
None.
Negative
None.
Insights
State Street holds a passive 5.1% stake in Ultragenyx as of 03/31/2026.
State Street Corporation's Schedule 13G reports 5,021,441 shares beneficially owned with shared voting power 4,769,004 and shared dispositive power 5,021,441. Schedule 13G status typically indicates passive investment intent under SEC rules.
Cash‑flow treatment and any plans to buy or sell are not stated in the excerpt; subsequent filings will show changes in ownership or voting if they occur.
Shared powers imply holdings managed through advisory or pooled vehicles.
The filing names multiple State Street advisory and trust entities (for example, SSGA Funds Management, Inc.), consistent with institutional management of client assets where voting/dispositive rights are exercised on a shared basis.
Investors tracking ownership concentration should note the 5.1% threshold disclosure and watch for any Schedule 13D or Form 4 filings that would signal activist intent or insider transactions.
Key Figures
Beneficial ownership:5,021,441 sharesPercent of class:5.1%Shared voting power:4,769,004 shares+1 more
4 metrics
Beneficial ownership5,021,441 sharesas of 03/31/2026
Percent of class5.1%Ultragenyx common stock
Shared voting power4,769,004 sharesas reported in Item 4
Shared dispositive power5,021,441 sharesas reported in Item 4
"State Street Corporation filed a Schedule 13G reporting beneficial ownership"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Shared dispositive powerfinancial
"Shared power to dispose or to direct the disposition of: 5,021,441"
Beneficially ownedfinancial
"Amount beneficially owned: 5021441.00 (b) Percent of class: 5.1 %"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
What stake does State Street Corporation report in ULTRAGENYX (RARE)?
State Street reports beneficial ownership of 5,021,441 shares, equal to 5.1% of Ultragenyx common stock as of 03/31/2026. The filing is a Schedule 13G signed on 05/12/2026.
Does the Schedule 13G indicate State Street controls voting of the shares?
The filing shows shared voting power of 4,769,004 shares, not sole voting control. It lists shared voting and dispositive powers, indicating collective management rather than unilateral control.
Which State Street entities are identified in the filing for RARE holdings?
The filing identifies advisory and trust affiliates including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and others as entities related to the reported holdings and classifications.
Does this Schedule 13G show State Street plans to sell or buy more RARE shares?
This Schedule 13G reports a passive beneficial ownership position; it does not state intentions to buy or sell additional shares. Transactional plans are not included in the provided excerpt.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
ULTRAGENYX PHARMACEUTICAL INC
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
90400D108
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
90400D108
1
Names of Reporting Persons
STATE STREET CORPORATION
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
MASSACHUSETTS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,769,004.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,021,441.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,021,441.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.1 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
ULTRAGENYX PHARMACEUTICAL INC
(b)
Address of issuer's principal executive offices:
60 LEVERONI COURT, NOVATO, CALIFORNIA, 94949
Item 2.
(a)
Name of person filing:
STATE STREET CORPORATION;
(b)
Address or principal business office or, if none, residence:
ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES
(c)
Citizenship:
MA
(d)
Title of class of securities:
COMMON STOCK
(e)
CUSIP Number(s):
90400D108
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
5021441.00
(b)
Percent of class:
5.1 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
4,769,004
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
5,021,441
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
NOT APPLICABLE
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
SSGA FUNDS MANAGEMENT, INC. (IA);STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA);STATE STREET GLOBAL ADVISORS LIMITED (IA);STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA);STATE STREET GLOBAL ADVISORS, LTD. (IA);
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
NOT APPLICABLE
Item 9.
Notice of Dissolution of Group.
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
NOT APPLICABLE
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
